资源类型：
会议/期刊
收录情况：
◇ SCIE
文章类型：
会议摘要
作者：
Zhou, Q.[1]
*
;
Pan, Y.[1]
;
Yang, X. -N.[1]
;
Yu, Q. -T.[2]
;
Zhao, W. -H.[2]
;
Zhang, T. -M.[3]
;
Liu, A. -W.[4]
;
Feng, W. -N.[5]
;
Dong, X. -R.[6]
;
Yang, Y.[7]
;
Zhao, M. -F.[8]
;
Wang, P. -L.[9]
;
Fan, Y.[10]
;
Luo, H.[11]
;
Wang, B. -H.[12]
;
Shu, Y. -S.[12]
;
Liu, Y.[13]
;
Zhao, J.[14]
;
Bu, Q.[15]
;
Li, J.[16]
;
Xu, F.[17]
;
Sun, L. -H.[17]
;
Liu, S. -Y. M.[18]
;
Wu, Y. -L.[1]
;
机构：
[1]Guangdong Acad Med Sci, Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
广东省人民医院
[2]Guangxi Med Univ, Affiliated Tumor Hosp, Dept Resp Oncol, Nanning, Peoples R China
[3]Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China
[4]Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[5]First Peoples Hosp Foshan, Pulm Oncol Dept, Foshan, Peoples R China
[6]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
华中科技大学同济医学院附属协和医院
[7]Third Peoples Hosp Chengdu, Dept Thorac Surg, Chengdu, Peoples R China
[8]China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China
[9]Zhejiang Univ, Affiliated Hosp 2, Dept Resp, Hangzhou, Peoples R China
[10]Zhejiang Canc Hosp, Zhejiang Canc Res Inst, Key Lab Diag & Treatment Technol Thorac Canc, Hangzhou, Peoples R China
浙江省肿瘤医院
[11]Canc Hosp Jiangxi Prov, Dept Thorac Radiotherapy, Nanchang, Peoples R China
[12]Northern Jiangsu Peoples Hosp, Dept Oncol, Yangzhou, Peoples R China
[13]Wuhan Cent Hosp, Dept Cardiothorac Surg, Wuhan, Peoples R China
[14]Peking Univ, Canc Hosp & Inst, Beijing Canc Hosp,Dept Thorac Oncol 1, Key Lab Carcinogenesis & Translat Res,Minist, Beijing, Peoples R China
[15]Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Peoples R China
[16]Sichuan Canc Hosp, Dept Med Oncol, Chengdu, Peoples R China
四川省肿瘤医院
[17]Nanchang Univ, Affiliated Hosp 1, Dept Resp Med, Nanchang, Peoples R China
[18]Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
出处：
JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S338-S338.
ISSN：
1556-0864
关键词：
EGFRm plus stage III NSCLC
aumolertinib introduction followed by MDT
personalized EGFR-TKI with MRD monitoring
WOS：
WOS:001337925602112
中科院(CAS)分区：
最新[2023]版：
大类
|
1 区
医学
小类
|
1 区
肿瘤学
1 区
呼吸系统
JCR分区：
最新[2023]版：
Q1
ONCOLOGY
Q1
RESPIRATORY SYSTEM
影响因子：
21.1
最新[2023版]
16.5
最新五年平均
21.1
出版当年[2023版]
0
出版当年五年平均
21.1
出版前一年[2023版]
第一作者：
Zhou, Q.
第一作者机构：
[1]Guangdong Acad Med Sci, Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Zhou Q.,Pan Y.,Yang X. -N.,et al.MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm plus Stage III NSCLC in the MDT Diagnostic Model (APPROACH)[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S338-S338.
APA：
Zhou, Q.,Pan, Y.,Yang, X. -N.,Yu, Q. -T.,Zhao, W. -H....&Wu, Y. -L..(2024).MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm plus Stage III NSCLC in the MDT Diagnostic Model (APPROACH).JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA：
Zhou, Q.,et al."MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm plus Stage III NSCLC in the MDT Diagnostic Model (APPROACH)".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S338-S338
医学